Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
The purpose this study is to assess whether a tirofiban regimen of a high-dose bolus plus a
shortened infusion duration compared to label-dosing eptifibatide in patients undergoing
percutaneous coronary intervention (PCI) is associated with a non-inferior composite rate of
death, PCI-related myocardial infarction, urgent target vessel revascularization or
in-hospital major bleeding within 48 hours following PCI or hospital discharge, whichever
comes first.